市場調查報告書
商品編碼
1451854
2024-2032 年單核苷酸多態性基因分型市場報告(按技術、應用和地區)Single Nucleotide Polymorphism Genotyping Market Report by Technology, Application, and Region 2024-2032 |
2023年全球單核苷酸多態性(SNP)基因分型市場規模達98億美元。展望未來, IMARC Group預計到2032年市場規模將達到379億美元,2024-2032年複合年成長率(CAGR)為15.79% 。不斷成長的基因型研究和開發活動、對個人化醫療和新型藥物輸送系統的需求不斷成長,以及對動植物原料遺傳分析的需求不斷成長,是推動市場的一些關鍵因素。
單核苷酸多態性 (SNP) 基因分型是一種透過檢查脫氧核糖核酸 (DNA) 序列中的特定位置來識別和分析個體遺傳變異的技術。它涉及確定個體 DNA 中特定 SNP 位點上存在的特定核苷酸。它依賴先進的分子生物學技術,例如聚合酶鍊式反應(PCR)和DNA測序,其中PCR擴增含有SNP的DNA片段,然後通過直接對擴增的DNA進行測序或使用其他方法來確定SNP位點的核苷酸。微陣列或等位基因特異性 PCR 等方法。它有助於了解群體遺傳學、遷移模式和演化歷史。它在確定藥物反應、預測疾病易感性以及根據特定基因譜客製化治療方面發揮著至關重要的作用。研究人員使用 SNP 基因分型來研究複雜疾病的遺傳基礎、識別遺傳風險因子並開發增強的診斷工具。
目前,由於基因型研究和開發活動的增加以及生物資訊學在開發各種疾病的診斷工具或有效療法中的應用,對SNP基因分型的需求不斷增加,這是支持市場成長的關鍵因素之一。此外,SNP 基因分型在癌症、心血管、阿茲海默症和氣喘等各種人類疾病的病因中的應用日益廣泛,提供了良好的市場前景。除此之外,世界各地對 SNP 基因分型建立遺傳關係、解決親子糾紛和協助刑事調查的需求不斷增加。這與蓬勃發展的醫療產業一起推動了市場的成長。此外,由於個人化醫療和新型藥物輸送系統的管道不斷增加,對藥物基因組學的需求不斷增加,正在加強市場的成長。除此之外,生命科學領域的許多SNP基因分型技術,如農業生物技術、診斷研究、製藥、藥物基因組學以及動物和牲畜育種,正在促進市場的成長。與此一致的是,全球糖尿病、心血管疾病和癌症盛行率的不斷上升正在對市場產生積極影響。此外,對動植物原料遺傳分析的需求不斷成長,也推動了市場的成長。
The global single nucleotide polymorphism (SNP) genotyping market size reached US$ 9.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 37.9 Billion by 2032, exhibiting a growth rate (CAGR) of 15.79% during 2024-2032. The growing genotype research and development activities, rising demand for personalized medicine and novel drug delivery systems, and increasing demand for genetic analysis in animal and plant feedstock represent some of the key factors driving the market.
Single nucleotide polymorphism (SNP) genotyping is a technique designed to identify and analyze genetic variations among individuals by examining specific locations within their deoxyribonucleic acid (DNA) sequence. It involves determining the specific nucleotide present at a particular SNP site in the DNA of an individual. It relies on advanced molecular biology techniques, such as polymerase chain reaction (PCR) and DNA sequencing, wherein PCR amplifies the DNA segment containing the SNP, and then the nucleotide at the SNP site is determined either by directly sequencing the amplified DNA or using other methods like microarrays or allele-specific PCR. It aids in understanding population genetics, migration patterns, and evolutionary history. It plays a crucial role in determining response to medications, predicting disease susceptibility, and tailoring treatments to specific genetic profiles. SNP genotyping is used by researchers to study the genetic basis of complex diseases, identify genetic risk factors, and develop enhanced diagnostic tools.
At present, the increasing demand for SNP genotyping on account of the rising genotype research and development activities and bioinformatics in the development of diagnostic tools or effective therapeutics for various diseases represents one of the crucial factors supporting the growth of the market. In addition, the growing utilization of SNP genotyping in the etiology of various human diseases, such as cancer, cardiovascular, Alzheimer's, and asthma, is offering a favorable market outlook. Besides this, there is a rise in the demand for SNP genotyping to establish genetic relationships, resolve paternity disputes, and assist in criminal investigations around the world. This, along with the thriving medical industry, is propelling the growth of the market. Moreover, the increasing demand for pharmacogenomics due to the rising pipeline for personalized medicine and novel drug delivery systems is strengthening the growth of the market. Apart from this, numerous technologies of SNP genotyping in the life science field, such as agricultural biotechnology, diagnostic research, pharmaceuticals, pharmacogenomics, and animal and livestock breeding, are contributing to the growth of the market. In line with this, the growing prevalence of diabetes, cardiovascular diseases, and cancer across the globe is positively influencing the market. Furthermore, the rising demand for genetic analysis in animal and plant feedstock is bolstering the growth of the market.
IMARC Group provides an analysis of the key trends in each segment of the global single nucleotide polymorphism (SNP) genotyping market, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on technology and application.
TaqMan SNP Genotyping
Massarray SNP Genotyping
SNP GeneChip Arrays
Others
The report has provided a detailed breakup and analysis of the single nucleotide polymorphism (SNP) genotyping market based on the technology. This includes TaqMan SNP genotyping, massarray SNP genotyping, SNP GeneChip arrays, and others.
Animal Genetics
Plant Improvement
Diagnostic Research
Pharmaceuticals and Pharmacogenomics
Agricultural Biotechnology
Others
A detailed breakup and analysis of the single nucleotide polymorphism (SNP) genotyping market based on the application has also been provided in the report. This includes animal genetics, plant improvement, diagnostic research, pharmaceuticals and pharmacogenomics, agricultural biotechnology, and others. According to the report, pharmaceuticals and pharmacogenomics accounted for the largest market share.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for single nucleotide polymorphism (SNP) genotyping. Some of the factors driving the North America single nucleotide polymorphism (SNP) genotyping market included favorable government policies towards proper diagnosis, increasing screening and treatment of fatal diseases, availability of enhanced research and development (R&D) facilities, etc.
The report has also provided a comprehensive analysis of the competitive landscape in the global single nucleotide polymorphism (SNP) genotyping market. Detailed profiles of all major companies have been provided. Some of the companies covered include Agilent Technologies Inc., Eurofins Genomics (Eurofins Scientific SE), Illumina Inc., Integrated DNA Technologies, Inc. (Danaher Corporation), LGC Limited, PREMIER Biosoft, Promega Corporation, QIAGEN N.V, Roche Holding AG, Thermo Fisher Scientific Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.